

Datasheet: HCA280

BATCH NUMBER 156959

Description:	HUMAN ANTI DENOSUMAB
Specificity:	DENOSUMAB
Other names:	PROLIA, XGEVA
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	AbD26295_hIgG1
Isotype:	IgG1
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Form	Human IgG1 antibody (kappa light chain) selected from the HuCAL® phage display library and expressed in a human cell line - liquid
Preparation	Purified IgG prepared by affinity chromatography on Protein A
Buffer Solution	Phosphate buffered saline
Preservative Stabilisers	0.01% Thiomersal
Approx. Protein Concentrations	IgG concentration 0.5 mg/ml
Immunogen	Denosumab
Specificity	Human Anti-Denosumab Antibody, clone AbD26295_hIgG1 is a paratope specific

anti-idiotypic antibody that specifically recognizes the free human monoclonal antibody denosumab. The antibody does not recognize free RANKL (receptor activator of nuclear factor kappa-B ligand) or denosumab in complex with human RANKL and can be used to measure free denosumab and biosimilar products.

Clone AbD26295_hlgG1 is a fully human recombinant monoclonal antibody with IgG1 isotype and is suitable as a reference standard in an anti-drug antibody (ADA) assay.

A pair of anti denosumab antibodies can be used to develop a pharmacokinetic (PK) bridging assay to measure free drug. This antibody, in full immunoglobulin format, is recommended as the detection antibody paired with clone AbD26296 ([HCA288](#)) in monovalent Fab format as the capture antibody.

Denosumab (Prolia, Xgeva) is a fully human monoclonal antibody (IgG2/kappa) for the treatment of osteoporosis, treatment-induced bone loss, bone metastases, multiple myeloma, and giant cell tumor of bone. The drug specifically binds to human RANKL a protein that acts as the primary signal to promote bone removal/resorption and prevents RANKL from activating its receptor, RANK, on the surface of osteoclasts and their precursors.

[View a summary of all anti-denosumab antibodies.](#)

Affinity	The monovalent intrinsic affinity of this antibody was measured as $K_D=1.8$ nM by real time, label-free molecular interaction analysis on immobilized denosumab
ELISA	This product may be used in direct or indirect ELISA and in an ELISA bridging assay as a detection antibody together, when conjugated to HRP, with HCA288 as the capture reagent. It is also suitable as a fully human control or calibrator antibody in an ADA bridging ELISA. Protocol: PK bridging ELISA to measure free drug Protocol: ADA bridging ELISA
Storage	Store at +4°C or at -20°C if preferred. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use
Guarantee	12 months from date of despatch
Acknowledgements	Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Prolia and Xgeva are registered trademarks of Amgen Inc.
Health And Safety Information	Material Safety Datasheet documentation #10094 available at: https://www.bio-rad-antibodies.com/SDS/HCA280 10094

Licensed Use For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad

Regulatory For research purposes only

Technical Advice Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the [HuCAL Antibodies Technical Manual](#)

Related Products

Recommended Useful Reagents

[HUMAN ANTI DENOSUMAB \(HCA281\)](#)

[HUMAN ANTI DENOSUMAB \(HCA282\)](#)

[HUMAN ANTI DENOSUMAB \(HCA288\)](#)

[HUMAN ANTI DENOSUMAB:HRP \(HCA280P\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK001P\)](#)

[HISPEC ASSAY DILUENT \(BUF049A\)](#)

North & South Tel: +1 800 265 7376

America Fax: +1 919 878 3751

Email: antibody_sales_us@bio-rad.com

Worldwide

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: antibody_sales_uk@bio-rad.com

Europe

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets

'M371717:200612'

Printed on 12 Aug 2023

© 2023 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)